nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—HTR2B—Sorafenib—thyroid cancer	0.243	0.486	CbGbCtD
Cabergoline—HTR2C—Sorafenib—thyroid cancer	0.158	0.317	CbGbCtD
Cabergoline—CYP3A4—Vandetanib—thyroid cancer	0.05	0.1	CbGbCtD
Cabergoline—CYP3A4—Sorafenib—thyroid cancer	0.0301	0.0603	CbGbCtD
Cabergoline—CYP3A4—Doxorubicin—thyroid cancer	0.0183	0.0366	CbGbCtD
Cabergoline—Neoplasm malignant—Sorafenib—thyroid cancer	0.00453	0.013	CcSEcCtD
Cabergoline—Cardiac failure—Vandetanib—thyroid cancer	0.00427	0.0123	CcSEcCtD
Cabergoline—Blood creatinine increased—Vandetanib—thyroid cancer	0.0039	0.0112	CcSEcCtD
Cabergoline—Influenza like illness—Sorafenib—thyroid cancer	0.00376	0.0108	CcSEcCtD
Cabergoline—Gastritis—Vandetanib—thyroid cancer	0.00369	0.0106	CcSEcCtD
Cabergoline—Influenza—Vandetanib—thyroid cancer	0.0036	0.0103	CcSEcCtD
Cabergoline—Pericardial effusion—Epirubicin—thyroid cancer	0.00349	0.01	CcSEcCtD
Cabergoline—Bronchitis—Vandetanib—thyroid cancer	0.00346	0.00995	CcSEcCtD
Cabergoline—Prostatic disorder—Epirubicin—thyroid cancer	0.00337	0.00967	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00335	0.00961	CcSEcCtD
Cabergoline—Pericarditis—Epirubicin—thyroid cancer	0.00331	0.0095	CcSEcCtD
Cabergoline—Weight decreased—Vandetanib—thyroid cancer	0.00326	0.00936	CcSEcCtD
Cabergoline—Pneumonia—Vandetanib—thyroid cancer	0.00323	0.00928	CcSEcCtD
Cabergoline—Pericardial effusion—Doxorubicin—thyroid cancer	0.00323	0.00927	CcSEcCtD
Cabergoline—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00322	0.00924	CcSEcCtD
Cabergoline—Depression—Vandetanib—thyroid cancer	0.0032	0.00919	CcSEcCtD
Cabergoline—Urinary tract infection—Vandetanib—thyroid cancer	0.00312	0.00896	CcSEcCtD
Cabergoline—Prostatic disorder—Doxorubicin—thyroid cancer	0.00311	0.00894	CcSEcCtD
Cabergoline—Pericarditis—Doxorubicin—thyroid cancer	0.00306	0.00879	CcSEcCtD
Cabergoline—Epistaxis—Vandetanib—thyroid cancer	0.00303	0.0087	CcSEcCtD
Cabergoline—Cardiac failure—Sorafenib—thyroid cancer	0.00288	0.00827	CcSEcCtD
Cabergoline—Visual impairment—Vandetanib—thyroid cancer	0.00278	0.00798	CcSEcCtD
Cabergoline—Cardiac disorder—Vandetanib—thyroid cancer	0.00268	0.00768	CcSEcCtD
Cabergoline—Arrhythmia—Vandetanib—thyroid cancer	0.00258	0.0074	CcSEcCtD
Cabergoline—Abdominal pain upper—Sorafenib—thyroid cancer	0.00257	0.00737	CcSEcCtD
Cabergoline—Alopecia—Vandetanib—thyroid cancer	0.00255	0.00732	CcSEcCtD
Cabergoline—Gastritis—Sorafenib—thyroid cancer	0.00249	0.00714	CcSEcCtD
Cabergoline—Muscle spasms—Vandetanib—thyroid cancer	0.00241	0.00693	CcSEcCtD
Cabergoline—Abdominal discomfort—Sorafenib—thyroid cancer	0.00233	0.00669	CcSEcCtD
Cabergoline—Loss of consciousness—Vandetanib—thyroid cancer	0.00221	0.00633	CcSEcCtD
Cabergoline—Weight decreased—Sorafenib—thyroid cancer	0.0022	0.00631	CcSEcCtD
Cabergoline—Pneumonia—Sorafenib—thyroid cancer	0.00218	0.00626	CcSEcCtD
Cabergoline—Hypertension—Vandetanib—thyroid cancer	0.00217	0.00622	CcSEcCtD
Cabergoline—Arthralgia—Vandetanib—thyroid cancer	0.00214	0.00614	CcSEcCtD
Cabergoline—Anxiety—Vandetanib—thyroid cancer	0.00213	0.00611	CcSEcCtD
Cabergoline—Hypokinesia—Epirubicin—thyroid cancer	0.00212	0.00609	CcSEcCtD
Cabergoline—Dry mouth—Vandetanib—thyroid cancer	0.00209	0.006	CcSEcCtD
Cabergoline—Oedema—Vandetanib—thyroid cancer	0.00205	0.00588	CcSEcCtD
Cabergoline—Epistaxis—Sorafenib—thyroid cancer	0.00204	0.00587	CcSEcCtD
Cabergoline—Hypokinesia—Doxorubicin—thyroid cancer	0.00196	0.00563	CcSEcCtD
Cabergoline—Pleural effusion—Epirubicin—thyroid cancer	0.00187	0.00537	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00187	0.00536	CcSEcCtD
Cabergoline—Insomnia—Vandetanib—thyroid cancer	0.00185	0.00532	CcSEcCtD
Cabergoline—Paraesthesia—Vandetanib—thyroid cancer	0.00184	0.00528	CcSEcCtD
Cabergoline—Dyspnoea—Vandetanib—thyroid cancer	0.00183	0.00524	CcSEcCtD
Cabergoline—Cardiac disorder—Sorafenib—thyroid cancer	0.0018	0.00518	CcSEcCtD
Cabergoline—Dyspepsia—Vandetanib—thyroid cancer	0.0018	0.00518	CcSEcCtD
Cabergoline—Decreased appetite—Vandetanib—thyroid cancer	0.00178	0.00511	CcSEcCtD
Cabergoline—Fatigue—Vandetanib—thyroid cancer	0.00177	0.00507	CcSEcCtD
Cabergoline—Constipation—Vandetanib—thyroid cancer	0.00175	0.00503	CcSEcCtD
Cabergoline—Pain—Vandetanib—thyroid cancer	0.00175	0.00503	CcSEcCtD
Cabergoline—Arrhythmia—Sorafenib—thyroid cancer	0.00174	0.00499	CcSEcCtD
Cabergoline—Pleural effusion—Doxorubicin—thyroid cancer	0.00173	0.00497	CcSEcCtD
Cabergoline—Alopecia—Sorafenib—thyroid cancer	0.00172	0.00493	CcSEcCtD
Cabergoline—Neoplasm malignant—Epirubicin—thyroid cancer	0.00168	0.00481	CcSEcCtD
Cabergoline—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00167	0.00481	CcSEcCtD
Cabergoline—Breast pain—Epirubicin—thyroid cancer	0.00164	0.00471	CcSEcCtD
Cabergoline—Muscle spasms—Sorafenib—thyroid cancer	0.00163	0.00467	CcSEcCtD
Cabergoline—Abdominal pain—Vandetanib—thyroid cancer	0.00162	0.00465	CcSEcCtD
Cabergoline—Arthropathy—Epirubicin—thyroid cancer	0.00157	0.00452	CcSEcCtD
Cabergoline—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00155	0.00445	CcSEcCtD
Cabergoline—Dyskinesia—Epirubicin—thyroid cancer	0.00152	0.00437	CcSEcCtD
Cabergoline—Syncope—Sorafenib—thyroid cancer	0.00152	0.00436	CcSEcCtD
Cabergoline—Breast pain—Doxorubicin—thyroid cancer	0.00152	0.00436	CcSEcCtD
Cabergoline—Loss of consciousness—Sorafenib—thyroid cancer	0.00149	0.00427	CcSEcCtD
Cabergoline—Asthenia—Vandetanib—thyroid cancer	0.00147	0.00422	CcSEcCtD
Cabergoline—Hypertension—Sorafenib—thyroid cancer	0.00146	0.0042	CcSEcCtD
Cabergoline—Arthropathy—Doxorubicin—thyroid cancer	0.00146	0.00418	CcSEcCtD
Cabergoline—Pruritus—Vandetanib—thyroid cancer	0.00145	0.00416	CcSEcCtD
Cabergoline—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00145	0.00416	CcSEcCtD
Cabergoline—Arthralgia—Sorafenib—thyroid cancer	0.00144	0.00414	CcSEcCtD
Cabergoline—Dry mouth—Sorafenib—thyroid cancer	0.00141	0.00405	CcSEcCtD
Cabergoline—Dyskinesia—Doxorubicin—thyroid cancer	0.00141	0.00405	CcSEcCtD
Cabergoline—Diarrhoea—Vandetanib—thyroid cancer	0.0014	0.00402	CcSEcCtD
Cabergoline—Influenza like illness—Epirubicin—thyroid cancer	0.00139	0.00399	CcSEcCtD
Cabergoline—Shock—Sorafenib—thyroid cancer	0.00136	0.0039	CcSEcCtD
Cabergoline—Dizziness—Vandetanib—thyroid cancer	0.00135	0.00389	CcSEcCtD
Cabergoline—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00134	0.00385	CcSEcCtD
Cabergoline—Anorexia—Sorafenib—thyroid cancer	0.00132	0.00378	CcSEcCtD
Cabergoline—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00131	0.00378	CcSEcCtD
Cabergoline—Vomiting—Vandetanib—thyroid cancer	0.0013	0.00374	CcSEcCtD
Cabergoline—Rash—Vandetanib—thyroid cancer	0.00129	0.00371	CcSEcCtD
Cabergoline—Dermatitis—Vandetanib—thyroid cancer	0.00129	0.0037	CcSEcCtD
Cabergoline—Influenza like illness—Doxorubicin—thyroid cancer	0.00129	0.00369	CcSEcCtD
Cabergoline—Headache—Vandetanib—thyroid cancer	0.00128	0.00368	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00126	0.00361	CcSEcCtD
Cabergoline—Abnormal vision—Epirubicin—thyroid cancer	0.00125	0.00358	CcSEcCtD
Cabergoline—Mental disability—Epirubicin—thyroid cancer	0.00124	0.00357	CcSEcCtD
Cabergoline—Dyspnoea—Sorafenib—thyroid cancer	0.00123	0.00354	CcSEcCtD
Cabergoline—Nausea—Vandetanib—thyroid cancer	0.00122	0.00349	CcSEcCtD
Cabergoline—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00122	0.00349	CcSEcCtD
Cabergoline—Dyspepsia—Sorafenib—thyroid cancer	0.00122	0.00349	CcSEcCtD
Cabergoline—Decreased appetite—Sorafenib—thyroid cancer	0.0012	0.00345	CcSEcCtD
Cabergoline—Fatigue—Sorafenib—thyroid cancer	0.00119	0.00342	CcSEcCtD
Cabergoline—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00119	0.00341	CcSEcCtD
Cabergoline—Pain—Sorafenib—thyroid cancer	0.00118	0.00339	CcSEcCtD
Cabergoline—Constipation—Sorafenib—thyroid cancer	0.00118	0.00339	CcSEcCtD
Cabergoline—Abnormal vision—Doxorubicin—thyroid cancer	0.00115	0.00332	CcSEcCtD
Cabergoline—Mental disability—Doxorubicin—thyroid cancer	0.00115	0.0033	CcSEcCtD
Cabergoline—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00113	0.00324	CcSEcCtD
Cabergoline—Hot flush—Epirubicin—thyroid cancer	0.00111	0.00319	CcSEcCtD
Cabergoline—Menopausal symptoms—Epirubicin—thyroid cancer	0.0011	0.00316	CcSEcCtD
Cabergoline—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.0011	0.00316	CcSEcCtD
Cabergoline—Abdominal pain—Sorafenib—thyroid cancer	0.00109	0.00314	CcSEcCtD
Cabergoline—Cardiac failure—Epirubicin—thyroid cancer	0.00106	0.00306	CcSEcCtD
Cabergoline—Osteoarthritis—Epirubicin—thyroid cancer	0.00104	0.00298	CcSEcCtD
Cabergoline—Hot flush—Doxorubicin—thyroid cancer	0.00103	0.00295	CcSEcCtD
Cabergoline—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00102	0.00293	CcSEcCtD
Cabergoline—Hypersensitivity—Sorafenib—thyroid cancer	0.00102	0.00292	CcSEcCtD
Cabergoline—Face oedema—Epirubicin—thyroid cancer	0.001	0.00288	CcSEcCtD
Cabergoline—Asthenia—Sorafenib—thyroid cancer	0.000991	0.00285	CcSEcCtD
Cabergoline—Cardiac failure—Doxorubicin—thyroid cancer	0.000985	0.00283	CcSEcCtD
Cabergoline—Pruritus—Sorafenib—thyroid cancer	0.000977	0.00281	CcSEcCtD
Cabergoline—Blood creatinine increased—Epirubicin—thyroid cancer	0.000973	0.00279	CcSEcCtD
Cabergoline—Osteoarthritis—Doxorubicin—thyroid cancer	0.000961	0.00276	CcSEcCtD
Cabergoline—Liver function test abnormal—Epirubicin—thyroid cancer	0.000959	0.00275	CcSEcCtD
Cabergoline—Abdominal pain upper—Epirubicin—thyroid cancer	0.000949	0.00272	CcSEcCtD
Cabergoline—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000949	0.00272	CcSEcCtD
Cabergoline—Diarrhoea—Sorafenib—thyroid cancer	0.000945	0.00271	CcSEcCtD
Cabergoline—Face oedema—Doxorubicin—thyroid cancer	0.000928	0.00266	CcSEcCtD
Cabergoline—Gastritis—Epirubicin—thyroid cancer	0.000919	0.00264	CcSEcCtD
Cabergoline—Dizziness—Sorafenib—thyroid cancer	0.000914	0.00262	CcSEcCtD
Cabergoline—Blood creatinine increased—Doxorubicin—thyroid cancer	0.0009	0.00259	CcSEcCtD
Cabergoline—Influenza—Epirubicin—thyroid cancer	0.000898	0.00258	CcSEcCtD
Cabergoline—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000887	0.00255	CcSEcCtD
Cabergoline—Vomiting—Sorafenib—thyroid cancer	0.000878	0.00252	CcSEcCtD
Cabergoline—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000878	0.00252	CcSEcCtD
Cabergoline—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000878	0.00252	CcSEcCtD
Cabergoline—Rash—Sorafenib—thyroid cancer	0.000871	0.0025	CcSEcCtD
Cabergoline—Dermatitis—Sorafenib—thyroid cancer	0.00087	0.0025	CcSEcCtD
Cabergoline—Headache—Sorafenib—thyroid cancer	0.000865	0.00249	CcSEcCtD
Cabergoline—Bronchitis—Epirubicin—thyroid cancer	0.000863	0.00248	CcSEcCtD
Cabergoline—Gastritis—Doxorubicin—thyroid cancer	0.000851	0.00244	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000834	0.0024	CcSEcCtD
Cabergoline—Influenza—Doxorubicin—thyroid cancer	0.000831	0.00239	CcSEcCtD
Cabergoline—Nausea—Sorafenib—thyroid cancer	0.000821	0.00236	CcSEcCtD
Cabergoline—Weight increased—Epirubicin—thyroid cancer	0.000817	0.00235	CcSEcCtD
Cabergoline—Weight decreased—Epirubicin—thyroid cancer	0.000812	0.00233	CcSEcCtD
Cabergoline—Pneumonia—Epirubicin—thyroid cancer	0.000805	0.00231	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—thyroid cancer	0.000799	0.00229	CcSEcCtD
Cabergoline—Urinary tract infection—Epirubicin—thyroid cancer	0.000778	0.00223	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000772	0.00222	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—thyroid cancer	0.000756	0.00217	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—thyroid cancer	0.000755	0.00217	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—thyroid cancer	0.000752	0.00216	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—thyroid cancer	0.000745	0.00214	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—thyroid cancer	0.00072	0.00207	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—thyroid cancer	0.00072	0.00207	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—thyroid cancer	0.000708	0.00203	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—thyroid cancer	0.000699	0.00201	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—thyroid cancer	0.000693	0.00199	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—thyroid cancer	0.000667	0.00192	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—thyroid cancer	0.000667	0.00191	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—thyroid cancer	0.000655	0.00188	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—thyroid cancer	0.000642	0.00184	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—thyroid cancer	0.000641	0.00184	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—thyroid cancer	0.000635	0.00182	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—thyroid cancer	0.000617	0.00177	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—thyroid cancer	0.000616	0.00177	CcSEcCtD
Cabergoline—Tension—Epirubicin—thyroid cancer	0.000614	0.00176	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—thyroid cancer	0.000608	0.00174	CcSEcCtD
Cabergoline—Back pain—Epirubicin—thyroid cancer	0.000605	0.00174	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—thyroid cancer	0.000601	0.00173	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—thyroid cancer	0.000594	0.00171	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—thyroid cancer	0.000588	0.00169	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—thyroid cancer	0.00058	0.00167	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—thyroid cancer	0.00057	0.00164	CcSEcCtD
Cabergoline—Tension—Doxorubicin—thyroid cancer	0.000568	0.00163	CcSEcCtD
Cabergoline—Malaise—Epirubicin—thyroid cancer	0.000564	0.00162	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—thyroid cancer	0.000562	0.00161	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—thyroid cancer	0.000562	0.00161	CcSEcCtD
Cabergoline—Syncope—Epirubicin—thyroid cancer	0.000561	0.00161	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—thyroid cancer	0.00056	0.00161	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—thyroid cancer	0.000557	0.0016	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—thyroid cancer	0.000553	0.00159	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—thyroid cancer	0.00055	0.00158	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—thyroid cancer	0.00054	0.00155	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000537	0.00154	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—thyroid cancer	0.000533	0.00153	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—thyroid cancer	0.000531	0.00152	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—thyroid cancer	0.000526	0.00151	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—thyroid cancer	0.000522	0.0015	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—thyroid cancer	0.000521	0.0015	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—thyroid cancer	0.00052	0.00149	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—thyroid cancer	0.000519	0.00149	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—thyroid cancer	0.000515	0.00148	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—thyroid cancer	0.000512	0.00147	CcSEcCtD
Cabergoline—Oedema—Epirubicin—thyroid cancer	0.000511	0.00147	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—thyroid cancer	0.000509	0.00146	CcSEcCtD
Cabergoline—Shock—Epirubicin—thyroid cancer	0.000502	0.00144	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—thyroid cancer	0.0005	0.00144	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—thyroid cancer	0.000494	0.00142	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—thyroid cancer	0.000493	0.00142	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—thyroid cancer	0.000491	0.00141	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—thyroid cancer	0.000487	0.0014	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—thyroid cancer	0.000487	0.0014	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—thyroid cancer	0.000482	0.00138	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—thyroid cancer	0.000477	0.00137	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—thyroid cancer	0.000476	0.00137	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—thyroid cancer	0.000472	0.00136	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000465	0.00134	CcSEcCtD
Cabergoline—Shock—Doxorubicin—thyroid cancer	0.000465	0.00133	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—thyroid cancer	0.000462	0.00133	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—thyroid cancer	0.000458	0.00132	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000457	0.00131	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—thyroid cancer	0.000455	0.00131	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—thyroid cancer	0.000454	0.0013	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—thyroid cancer	0.00045	0.00129	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—thyroid cancer	0.000449	0.00129	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—thyroid cancer	0.000444	0.00127	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—thyroid cancer	0.000441	0.00127	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—thyroid cancer	0.00044	0.00126	CcSEcCtD
Cabergoline—Constipation—Epirubicin—thyroid cancer	0.000437	0.00125	CcSEcCtD
Cabergoline—Pain—Epirubicin—thyroid cancer	0.000437	0.00125	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00043	0.00124	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—thyroid cancer	0.000427	0.00123	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—thyroid cancer	0.000424	0.00122	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—thyroid cancer	0.000421	0.00121	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—thyroid cancer	0.000421	0.00121	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—thyroid cancer	0.00042	0.00121	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000418	0.0012	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—thyroid cancer	0.000416	0.00119	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—thyroid cancer	0.000411	0.00118	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—thyroid cancer	0.000407	0.00117	CcSEcCtD
Cabergoline—Pain—Doxorubicin—thyroid cancer	0.000404	0.00116	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—thyroid cancer	0.000404	0.00116	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—thyroid cancer	0.000404	0.00116	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—thyroid cancer	0.000389	0.00112	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000386	0.00111	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—thyroid cancer	0.000376	0.00108	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—thyroid cancer	0.000373	0.00107	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—thyroid cancer	0.000366	0.00105	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—thyroid cancer	0.000361	0.00104	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—thyroid cancer	0.000349	0.001	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—thyroid cancer	0.000348	0.001	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—thyroid cancer	0.000339	0.000973	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—thyroid cancer	0.000338	0.00097	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—thyroid cancer	0.000334	0.00096	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—thyroid cancer	0.000325	0.000932	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—thyroid cancer	0.000323	0.000928	CcSEcCtD
Cabergoline—Rash—Epirubicin—thyroid cancer	0.000322	0.000924	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—thyroid cancer	0.000322	0.000924	CcSEcCtD
Cabergoline—Headache—Epirubicin—thyroid cancer	0.00032	0.000919	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—thyroid cancer	0.000312	0.000897	CcSEcCtD
Cabergoline—Nausea—Epirubicin—thyroid cancer	0.000303	0.000871	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—thyroid cancer	0.0003	0.000863	CcSEcCtD
Cabergoline—Rash—Doxorubicin—thyroid cancer	0.000298	0.000855	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—thyroid cancer	0.000298	0.000855	CcSEcCtD
Cabergoline—Headache—Doxorubicin—thyroid cancer	0.000296	0.00085	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—thyroid cancer	0.000281	0.000806	CcSEcCtD
Cabergoline—ADRA1A—Signaling Pathways—TERT—thyroid cancer	2.78e-05	0.000182	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—HRAS—thyroid cancer	2.77e-05	0.000182	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—KRAS—thyroid cancer	2.77e-05	0.000182	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	2.77e-05	0.000182	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HIF1A—thyroid cancer	2.76e-05	0.000181	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.75e-05	0.000181	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—KRAS—thyroid cancer	2.73e-05	0.000179	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—KRAS—thyroid cancer	2.73e-05	0.000179	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—HRAS—thyroid cancer	2.73e-05	0.000179	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—BRAF—thyroid cancer	2.72e-05	0.000179	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	2.71e-05	0.000178	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.71e-05	0.000178	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—BRAF—thyroid cancer	2.69e-05	0.000177	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TPR—thyroid cancer	2.69e-05	0.000177	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—NRAS—thyroid cancer	2.68e-05	0.000176	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—BRAF—thyroid cancer	2.66e-05	0.000175	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	2.66e-05	0.000174	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	2.66e-05	0.000174	CbGpPWpGaD
Cabergoline—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	2.66e-05	0.000174	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.65e-05	0.000174	CbGpPWpGaD
Cabergoline—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	2.64e-05	0.000173	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	2.63e-05	0.000173	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—HRAS—thyroid cancer	2.61e-05	0.000172	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—BRAF—thyroid cancer	2.6e-05	0.000171	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.59e-05	0.00017	CbGpPWpGaD
Cabergoline—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	2.58e-05	0.00017	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TERT—thyroid cancer	2.58e-05	0.000169	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—CCND1—thyroid cancer	2.56e-05	0.000168	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—CCND1—thyroid cancer	2.54e-05	0.000167	CbGpPWpGaD
Cabergoline—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	2.54e-05	0.000167	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	2.52e-05	0.000165	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PPARG—thyroid cancer	2.51e-05	0.000165	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.5e-05	0.000164	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—CCND1—thyroid cancer	2.49e-05	0.000164	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	2.49e-05	0.000163	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	2.48e-05	0.000163	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—PTEN—thyroid cancer	2.47e-05	0.000162	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	2.47e-05	0.000162	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—KRAS—thyroid cancer	2.47e-05	0.000162	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—KRAS—thyroid cancer	2.46e-05	0.000162	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—PTEN—thyroid cancer	2.46e-05	0.000161	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—CCND1—thyroid cancer	2.45e-05	0.000161	CbGpPWpGaD
Cabergoline—ADRA2A—Hemostasis—AKT1—thyroid cancer	2.45e-05	0.000161	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—KRAS—thyroid cancer	2.44e-05	0.00016	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PTGS2—thyroid cancer	2.43e-05	0.00016	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—NRAS—thyroid cancer	2.43e-05	0.00016	CbGpPWpGaD
Cabergoline—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.43e-05	0.000159	CbGpPWpGaD
Cabergoline—HTR7—Signaling by GPCR—AKT1—thyroid cancer	2.41e-05	0.000158	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PTEN—thyroid cancer	2.4e-05	0.000158	CbGpPWpGaD
Cabergoline—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	2.4e-05	0.000157	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.39e-05	0.000157	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	2.38e-05	0.000156	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	2.37e-05	0.000156	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PTEN—thyroid cancer	2.37e-05	0.000155	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—HRAS—thyroid cancer	2.35e-05	0.000155	CbGpPWpGaD
Cabergoline—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	2.35e-05	0.000154	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—CCND1—thyroid cancer	2.34e-05	0.000154	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	2.34e-05	0.000154	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—HRAS—thyroid cancer	2.32e-05	0.000153	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—HRAS—thyroid cancer	2.32e-05	0.000153	CbGpPWpGaD
Cabergoline—DRD4—Signaling by GPCR—AKT1—thyroid cancer	2.31e-05	0.000152	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	2.3e-05	0.000151	CbGpPWpGaD
Cabergoline—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	2.29e-05	0.00015	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—BRAF—thyroid cancer	2.28e-05	0.00015	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	2.27e-05	0.000149	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PTEN—thyroid cancer	2.26e-05	0.000148	CbGpPWpGaD
Cabergoline—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	2.26e-05	0.000148	CbGpPWpGaD
Cabergoline—ADRA1D—GPCR downstream signaling—AKT1—thyroid cancer	2.26e-05	0.000148	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—BRAF—thyroid cancer	2.25e-05	0.000148	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—CCND1—thyroid cancer	2.21e-05	0.000145	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—NRAS—thyroid cancer	2.21e-05	0.000145	CbGpPWpGaD
Cabergoline—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	2.2e-05	0.000145	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	2.2e-05	0.000144	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—NRAS—thyroid cancer	2.19e-05	0.000144	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—TP53—thyroid cancer	2.19e-05	0.000144	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—CCND1—thyroid cancer	2.18e-05	0.000143	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—CCND1—thyroid cancer	2.18e-05	0.000143	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	2.17e-05	0.000143	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—NRAS—thyroid cancer	2.15e-05	0.000141	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PTEN—thyroid cancer	2.13e-05	0.00014	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PTEN—thyroid cancer	2.12e-05	0.000139	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	2.12e-05	0.000139	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—NRAS—thyroid cancer	2.11e-05	0.000139	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PTEN—thyroid cancer	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PTEN—thyroid cancer	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—HRAS—thyroid cancer	2.1e-05	0.000138	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—HRAS—thyroid cancer	2.09e-05	0.000137	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—KRAS—thyroid cancer	2.09e-05	0.000137	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—AKT1—thyroid cancer	2.08e-05	0.000136	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—HRAS—thyroid cancer	2.07e-05	0.000136	CbGpPWpGaD
Cabergoline—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	2.06e-05	0.000135	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	2.06e-05	0.000135	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—AKT1—thyroid cancer	2.05e-05	0.000135	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—AKT1—thyroid cancer	2.05e-05	0.000135	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	2.04e-05	0.000134	CbGpPWpGaD
Cabergoline—ADRA2B—GPCR downstream signaling—AKT1—thyroid cancer	2.04e-05	0.000134	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	2.02e-05	0.000133	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.02e-05	0.000132	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—NRAS—thyroid cancer	2.02e-05	0.000132	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	2.01e-05	0.000132	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	2.01e-05	0.000132	CbGpPWpGaD
Cabergoline—ADRB2—GPCR downstream signaling—AKT1—thyroid cancer	2.01e-05	0.000132	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CCND1—thyroid cancer	1.98e-05	0.00013	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTGS2—thyroid cancer	1.97e-05	0.00013	CbGpPWpGaD
Cabergoline—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.97e-05	0.000129	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CCND1—thyroid cancer	1.97e-05	0.000129	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	1.96e-05	0.000129	CbGpPWpGaD
Cabergoline—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.96e-05	0.000129	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CCND1—thyroid cancer	1.94e-05	0.000127	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	1.93e-05	0.000127	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PTEN—thyroid cancer	1.92e-05	0.000126	CbGpPWpGaD
Cabergoline—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	1.9e-05	0.000125	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—NRAS—thyroid cancer	1.9e-05	0.000125	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—KRAS—thyroid cancer	1.9e-05	0.000125	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.9e-05	0.000125	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PTEN—thyroid cancer	1.9e-05	0.000125	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.89e-05	0.000124	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.89e-05	0.000124	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—NRAS—thyroid cancer	1.88e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—NRAS—thyroid cancer	1.88e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	1.87e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PTEN—thyroid cancer	1.87e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	1.87e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	1.87e-05	0.000123	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—AKT1—thyroid cancer	1.85e-05	0.000122	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—AKT1—thyroid cancer	1.85e-05	0.000121	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.85e-05	0.000121	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	1.84e-05	0.000121	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.83e-05	0.00012	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—AKT1—thyroid cancer	1.83e-05	0.00012	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.82e-05	0.00012	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—KRAS—thyroid cancer	1.82e-05	0.000119	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	1.81e-05	0.000119	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.79e-05	0.000117	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.78e-05	0.000117	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.78e-05	0.000117	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	1.77e-05	0.000116	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.75e-05	0.000115	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	1.74e-05	0.000115	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.73e-05	0.000114	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	1.73e-05	0.000114	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.73e-05	0.000113	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTEN—thyroid cancer	1.72e-05	0.000113	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.71e-05	0.000112	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NRAS—thyroid cancer	1.71e-05	0.000112	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	1.7e-05	0.000112	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.7e-05	0.000112	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—RXRA—thyroid cancer	1.69e-05	0.000111	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—thyroid cancer	1.69e-05	0.000111	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—thyroid cancer	1.69e-05	0.000111	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.68e-05	0.00011	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—thyroid cancer	1.67e-05	0.00011	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—thyroid cancer	1.67e-05	0.000109	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1.66e-05	0.000109	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.64e-05	0.000108	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.64e-05	0.000108	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—thyroid cancer	1.64e-05	0.000107	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.63e-05	0.000107	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.63e-05	0.000107	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—thyroid cancer	1.61e-05	0.000106	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—thyroid cancer	1.61e-05	0.000106	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—thyroid cancer	1.61e-05	0.000106	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—thyroid cancer	1.61e-05	0.000106	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—thyroid cancer	1.61e-05	0.000106	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	1.61e-05	0.000105	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—thyroid cancer	1.6e-05	0.000105	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	1.59e-05	0.000104	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.58e-05	0.000104	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	1.58e-05	0.000104	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.57e-05	0.000103	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—thyroid cancer	1.57e-05	0.000103	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	1.56e-05	0.000102	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	1.55e-05	0.000102	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	1.55e-05	0.000102	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—thyroid cancer	1.54e-05	0.000101	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.54e-05	0.000101	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.54e-05	0.000101	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	1.51e-05	9.93e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	1.49e-05	9.8e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.47e-05	9.68e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—thyroid cancer	1.47e-05	9.66e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—thyroid cancer	1.46e-05	9.57e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—thyroid cancer	1.45e-05	9.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	1.44e-05	9.45e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—thyroid cancer	1.44e-05	9.45e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.43e-05	9.42e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—thyroid cancer	1.43e-05	9.42e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—thyroid cancer	1.43e-05	9.42e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—thyroid cancer	1.42e-05	9.36e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—thyroid cancer	1.42e-05	9.29e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.41e-05	9.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.41e-05	9.24e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	1.4e-05	9.22e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.4e-05	9.19e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—thyroid cancer	1.39e-05	9.13e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—thyroid cancer	1.39e-05	9.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	1.38e-05	9.08e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—thyroid cancer	1.37e-05	9.01e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—thyroid cancer	1.37e-05	9.01e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—thyroid cancer	1.36e-05	8.96e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	1.36e-05	8.94e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	1.34e-05	8.8e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—thyroid cancer	1.31e-05	8.58e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.3e-05	8.55e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—thyroid cancer	1.3e-05	8.5e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.28e-05	8.44e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—thyroid cancer	1.28e-05	8.4e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—thyroid cancer	1.25e-05	8.21e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—thyroid cancer	1.25e-05	8.21e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.24e-05	8.17e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—thyroid cancer	1.24e-05	8.13e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—thyroid cancer	1.23e-05	8.11e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—thyroid cancer	1.23e-05	8.06e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—thyroid cancer	1.22e-05	8.03e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—thyroid cancer	1.22e-05	8.02e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.22e-05	7.98e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—thyroid cancer	1.21e-05	7.95e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—thyroid cancer	1.21e-05	7.95e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—thyroid cancer	1.21e-05	7.94e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—thyroid cancer	1.2e-05	7.85e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—thyroid cancer	1.19e-05	7.82e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	1.19e-05	7.81e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1.19e-05	7.81e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	1.16e-05	7.6e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	1.14e-05	7.48e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	1.11e-05	7.26e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—thyroid cancer	1.1e-05	7.25e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—thyroid cancer	1.1e-05	7.21e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—thyroid cancer	1.09e-05	7.18e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—thyroid cancer	1.08e-05	7.09e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—thyroid cancer	1.08e-05	7.09e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—thyroid cancer	1.07e-05	7.02e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—thyroid cancer	1.06e-05	6.94e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—thyroid cancer	1.06e-05	6.93e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—thyroid cancer	1.05e-05	6.9e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—thyroid cancer	1.05e-05	6.89e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—thyroid cancer	1.03e-05	6.78e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	1.02e-05	6.71e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	1.01e-05	6.64e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	1.01e-05	6.6e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—thyroid cancer	9.92e-06	6.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—thyroid cancer	9.83e-06	6.45e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	9.4e-06	6.17e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—thyroid cancer	9.27e-06	6.09e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—thyroid cancer	9.12e-06	5.99e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	8.93e-06	5.86e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—thyroid cancer	8.41e-06	5.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	8.3e-06	5.45e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—thyroid cancer	7.34e-06	4.82e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—thyroid cancer	4.23e-06	2.78e-05	CbGpPWpGaD
